News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Anand Patel: Myeloid neoplasms after MTX have features more similar to de-novo
Photo from Anand Patel/X
Jul 24, 2024, 00:57

Anand Patel: Myeloid neoplasms after MTX have features more similar to de-novo

Anand Patel, Assistant Professor and Director of the Inpatient Leukemia Service at the University of Chicago, shared a post on X/Twitter:

“We often discuss if myeloid neoplasms after MTX therapy have high-risk features/cytogenetics – this report found myeloid neoplasms after MTX have features more similar to de-novo disease than t-MN.”

Source: Anand Patel/X

Anand Patel

Authors: Mihir D. Wechalekar, Lin-Pierre Zhao, Monika M. Kutyna, Lih En Hong, Joule Li, Kevin Hung, Hamish S. Scott, Anna Brown, Christopher C. Hahn, Karin Kassahn, Dariusz Ladon, David T. Yeung, Daniel Thomas, Mrinal Patnaik, Susanna Proudman, Lionel Ades, Mithun V. Shah, Chung H. Kok and Devendra K. Hiwase

Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features

Anand Patel Anna Brown cancer Christopher C. Hahn Chung H. Kok Daniel Thomas Dariusz Ladon David T. Yeung Devendra K. Hiwase Hamish S. Scott Joule Li Karin Kassahn Kevin Hung Lih En Hong Lin-Pierre Zhao Lionel Ades Mihir D. Wechalekar Mithun V Shah Monika M. Kutyna Mrinal Patnaik MTX myeloid neoplasms OncoDaily Oncology Susanna Proudman University of Chicago
Special Coverage
Blog
Nov 13, 2024, 10:52
Johnson & Johnson Seeks Approval for DARZALEX FASPRO as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma
Blog
Nov 13, 2024, 10:47
FDA approves obecabtagene autoleucel for relapsed or refractory B-cell precursor ALL
Blog
Nov 13, 2024, 10:45
OncoInfluencers to Follow on Social Media: Dr. Nitin Jain
Insight
Nov 13, 2024, 10:37
UCLA: Combination approach shows promise for treating rare, aggressive cancers
Opinion
Nov 13, 2024, 10:32
The 6th Biennial Miami Epigenetics and Cancer Symposium to be held in Sylvester Comprehensive Cancer Center
Blog
Nov 13, 2024, 10:16
Highlights from IU Simon Comprehensive Cancer Center’s End Lung Cancer Now Gathering - Hoosier Cancer Research Network
Blog
Nov 13, 2024, 10:06
A first-in-class Antibody Drug Conjugate that works by directly stimulating the immune system
Blog
Nov 13, 2024, 09:55
Moderna Incorporation announced the awardees of its 2024 Australia Fellowship Program
Blog
Nov 13, 2024, 09:39
AI tools to improve diagnosis and therapy in neuro-oncology
Insight
Nov 13, 2024, 09:27
Nikki Rossetti et al. on Early-Stage Lung Cancer in the Era of Lung Cancer Screening
Blog
Nov 13, 2024, 09:14
Yüksel Ürün: Key takeaways on high-risk and locally advanced prostate cancer from António Rui Azevedo Freitas
Blog
Nov 13, 2024, 09:11
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy